403 / 1631
24
Hilal
1
, Greer
2
, Crump
3
, LaCasce et al
4
, NEM 2018
•
mPFS added more pts to ABVD; 5 had Deauville-3
1
•
Discontinuation due to tox, lack of CR, new treatment without
progression may obscure PFS
1,3
•
Revised calculation: 84% for A-AVD vs 82% for ABVD (ns)
1
•
Non-PET guided treatment outdated
1
•
Cost for A+AVD is $850.000 vs 18.000 for ABVD
2
•
Further therapy potentially subject to investigator bias
3
•
Not adequate for praxis changing
4
ECHELON-1: Phase III Trial
Letters and comments